The directors and management of N1 Technologies Inc. announced that the company has filed a new Biotech Patent with the USPTO for its VIRITRON VDX Bacteriophage Treatment. The company is a leader in Nanotechnology research, and now has focused on entering the Biotechnology arena with its latest discovery. The VIRITRON VDX biopharmaceutical is a Genetically Modified Bacteriophage that is highly effective in fighting antibiotic resistant Staphylococcus infections. A Bacteriophage is a natural organism that has been proven in various human trials to be highly effective at fighting various infectious bacteria.N1 Technologies intends to develop a treatment for Staph infections based on this unique modified organism. The company is working to develop a treatment for antibiotic resistant strains of bacterial infections.